

Treatment Outcomes of Adenotonsillectomy for Children with Obstructive Sleep Apnea: A Prospective Longitudinal Study

Yu-Shu Huang, MD^{1,6}; Christian Guilleminault, DM, MD, DBiol^{2,6}; Li-Ang Lee, MD³; Cheng-Hui Lin, MD⁴; Fan-Ming Hwang, PhD⁵

¹Department of Child Psychiatry and Sleep Center, Chang Gung Memorial Hospital and College of Medicine, Taoyuan, Taiwan; ²Stanford University Sleep Medicine Division, Stanford, CA; ³Department of Otolaryngology and Sleep Center, Chang Gung Memorial Hospital and College of Medicine, Taoyuan, Taiwan; ⁴Department of Cranio-Facial Center and Sleep Center, Chang Gung Memorial Hospital and College of Medicine, Taoyuan, Taiwan; ⁵Department of Education, National Chia-Yi University, Chiayi, Taiwan; ⁶Department of Clinical Psychology College of Medicine, FUJEN Catholic University, Taipei, Taiwan

Objective: To evaluate the efficacy of adenotonsillectomy (AT) in the treatment of children with obstructive sleep apnea (OSA) in a 3-y prospective, longitudinal study with analysis of risk factors of recurrence of OSA.

Study Design: An investigation of children (6 to 12 y old) with OSA documented at entry and followed posttreatment at 6, 12, 24, and 36 mo with examination, questionnaires, and polysomnography.

Multivariate generalized linear modeling and hierarchical linear models analysis were used to determine contributors to suboptimal long-term resolution of OSA, and Generalized Linear Models were used for analysis of risk factors of recurrence.

Results: Of the 135 children, 88 terminated the study at 36 months post-AT. These 88 children (boys = 72, mean age = 8.9 ± 2.7 years vs boys 8.9 ± 2.04 y, girls: 8.8 ± 2.07 y; body mass index [BMI] = 19.5 ± 4.6 kg/m²) had a preoperative mean apnea-hypopnea index (AHI₀) of 13.54 ± 7.23 and a mean postoperative AHI at 6 mo (AHI₆) of 3.47 ± 8.41 events/h (with AHI₆ > 1 = 53.4% of 88 children). A progressive increase in AHI was noted with a mean AHI₃₆ = 6.48 ± 5.57 events/h and AHI₃₆ > 1 = 68% of the studied group. Change in AHI was associated with changes in the OSA-18 questionnaire.

The residual pediatric OSA after AT was significantly associated with BMI, AHI, enuresis, and allergic rhinitis before surgery. From 6 to 36 mo after AT, recurrence of pediatric OSA was significantly associated with enuresis, age (for the 24- to 36-mo period), postsurgery AHI₆ (severity), and the rate of change in BMI and body weight.

Conclusions: Adenotonsillectomy leads to significant improvement in apnea-hypopnea index, though generally with incomplete resolution, but a worsening over time was observed in 68% of our cases.

Keywords: adenotonsillectomy, comorbidity, obstructive sleep apnea, polysomnography, treatment outcomes

Citation: Huang YS; Guilleminault C; Lee LA; Lin CH; Hwang FM. Treatment outcomes of adenotonsillectomy for children with obstructive sleep apnea: a prospective longitudinal study. *SLEEP* 2014;37(1):71-76.

INTRODUCTION

Obstructive sleep apnea (OSA) syndrome is a highly prevalent condition in children and characterized by snoring, witnessed apnea, unrefreshing sleep, and excessive daytime sleepiness.^{1,2} Children with OSA experience recurrent periods of elevated upper airway resistance during sleep due to partial or complete upper airway obstruction, which results in snoring, episodic oxyhemoglobin desaturation, hypercapnia, and repeated arousals.^{3,4} The respiratory disturbance of recurrent hypoxia-reoxygenation episodes during the night is associated with an increased risk of suboptimal growth, poor sleep quality, neurocognitive dysfunction, behavioral problems, overweight status, and cardiovascular disease in childhood.⁵⁻⁸ The prevalence of OSA is approximately 2-3% in children,^{9,10} and current studies have evaluated the influence of OSA on various associated morbidities^{5-8,11} and tried to identify the factors predicting poor treatment outcome.¹²

The choice of therapy for OSA is predicated on the etiology, severity, and individual history of the increased upper airway resistance. The timely diagnosis and appropriate treatment of OSA is especially important, because untreated OSA can account for markedly increased health care costs.¹³⁻¹⁵ Adenotonsillar hypertrophy is considered an important factor in the development of OSA in otherwise healthy children. Adenotonsillectomy (AT) is recommended as the first line of treatment for childhood OSA by the American Academy of Pediatrics,¹ and the effectiveness of AT in the treatment of children with OSA has been confirmed by several studies.¹⁵⁻¹⁷ However, some studies examining the efficacy and outcomes of AT in pediatric OSA showed incomplete resolution of OSA after surgery.¹²⁻¹⁷ For example, nonobese children with severe OSA and chronic asthma were found to be at higher risk of residual OSA in a recent multicenter retrospective study.¹² In addition, few studies have evaluated the overall long-term efficacy of AT in the treatment of children with OSA. Thus, this 3-y prospective, longitudinal study aimed to delineate factors contributing to potential post-AT OSA through careful examination of demographic and pre- and post-AT polysomnography (PSG) information. In our geographical location, the mean age for AT at the time of the study was approximately 8 y, and such age for surgery was based on two factors: usual recommendations made by ear, nose, and throat (ENT) surgeons when AT was considered, and reluctance of parents in our culture to have their children undergo nonemergency surgery.

Submitted for publication February, 2013

Submitted in final revised form October, 2013

Accepted for publication October, 2013

Address correspondence to: Christian Guilleminault, DM, MD, DBiol, Stanford University Sleep Medicine Division, 450 Broadway Street, MC 5704, Redwood City, CA 94063; Tel: (650) 723-6601; E-mail: cguil@stanford.edu

METHODS

Starting in August 2007, children between the ages of 6 and 12 y with signs and symptoms of a sleep disturbance, including snoring, mouth breathing, and witnessed breath holding, lasting for at least 3 mo, were evaluated prospectively using a standardized history and physical examination, neurocognitive and psychological testing, and PSG in the sleep center of Chang Gung Memorial Hospital (CGMH). The CGMH sleep clinic is a multidisciplinary clinic with expertise in the management of pediatric sleep apnea and is the only accredited pediatric sleep laboratory in Taiwan.

The inclusion criteria for subjects, based on PSG, were an obstructive apnea-hypopnea index (AHI, the number of apnea and hypopnea events per hour of sleep) greater than one event/h or a respiratory disturbance index (RDI) of more than five events/h with clinical symptoms. Both patients and parents agreed to participate in this longitudinal study and were willing to sign informed consent.

Exclusion criteria for the children were previous AT, craniofacial abnormalities, neuromuscular disease, or other significant medical, psychiatric, or genetic disorders, and obesity (obesity was defined based on Taiwan general public health tables, taking into consideration age and body mass index (BMI) in kg/m^2).¹⁸

This prospective study was approved by the institutional review board of CGMH, and the caregivers (parents) signed informed consent before their children were enrolled for study.

Procedure

All subjects underwent a routine medical history and physical examination by an otolaryngologist, a craniofacial surgeon, a pediatrician, and a child psychiatrist for assessment of associated comorbidities.

A standardized datasheet for patient demographic data, including age, sex, height, weight and all systemic comorbidities, was checked by child psychiatrists.

The ENT examination was performed by an otolaryngologist and a craniofacial surgeon. Tonsillar size was graded as follows: (1) small tonsils confined to the tonsillar pillars; (2) tonsils that extended just outside the pillars; (3) tonsils that extended outside the pillars but did not meet at the midline; (4) large tonsils that met at the midline.¹⁹ Adenoid tissue was examined with a lateral x-ray film of the neck or a flexible fiberoptic endoscope. The amount of obstruction was categorized into four grades (grade 0 = 0-25%, grade 1 = 25-50%, grade 2 = 50-75%, and grade 3 = 75-100%). Allergic rhinitis was confirmed by a specific immunoglobulin E (IgE) blood test (ImmunoCAP® 100; Phadia, Uppsala, Sweden), and duration and persistence of symptoms and comorbidities according to the Allergic Rhinitis and its Impact on Asthma (ARIA) classification.

Questionnaire evaluation: Parents completed the obstructive sleep disorder questionnaire (OSA-18).^{20,21} It is a subjective questionnaire that contains 18 items and covers quality of life. The items are divided into six domains: sleep disturbance, physical suffering, emotional distress, daytime problems, caregiver concerns, and total quality of life.^{20,21}

During the evaluation period, children underwent other mental and cognitive tests not presented here.

Once the clinical evaluation was complete, a standard overnight PSG with simultaneous video recording was used for

each subject in the hospital sleep laboratory preoperatively and 6 mo (AHI₆), 12 mo (AHI₁₂), 24 mo (AHI₂₄), and 36 mo (AHI₃₆) after AT. All children were instructed to discontinue any medication (or PSG was scheduled at least 7 days after discontinuation of medications prescribed for acute health problems prior to PSG). A family member was required to be present for all nocturnal PSG recordings. Sleep and wake were scored using the international criteria of Rechtschaffen and Kales²² with identification of stages 3 and 4, and identification of the onset of abnormal behavior to a specific sleep stage. EEG arousal was defined according to the guidelines of the American Sleep Disorders Association.²³ Abnormal breathing events during sleep were analyzed according to the definitions of an apnea and hypopnea as outlined by the American Academy of Sleep Medicine (AASM),²³ and the definition of flow limitation with abnormal increase in respiratory effort leading to arousals as outlined by Lin and Guilleminault.²⁴ Based on these definitions, the AHI and a respiratory disturbance index (RDI, the number of apneas, hypopneas, and respiratory effort-related arousals per hour of sleep) were calculated. Periodic limb movement (PLM) was defined according to the AASM scoring rules,²³ with a PLM index (PLMI) > 5 per hour being considered abnormal. PLMs associated with breathing events were not scored, and only those independent of apnea/hypopnea were considered. Abnormal behavior on video was noted when present. PSG scoring was performed by a technician blind to the clinical status of the child.

All children were given antileucotriene medication for 6 mo post-AT.

We followed the children posttreatment at 6, 12, 24, and 36 mo with the same examination, questionnaires, and PSG.

Statistical Analyses

Descriptive statistics were performed. Considering the missing data in longitudinal studies and the evolution of AT over time, multivariate generalized linear model (GLM) and hierarchical linear models (HLM) analyses were used to determine contributors to residual sleep apnea at various time points post-AT. GLM statistics were used to analyze the risk factors for OSA recurrence after AT looking at the entire follow-up period. We used HLM analyses to investigate the changes during the different follow-up points (AT_{6,12,24,36}): because there were different numbers of subjects at each follow-up-point, a two-level model was used. We analyzed fixed effects in level one, and random effects in level two. The coefficient of level one (fixed effects) was the intraclass correlation (ICC) which was, in our model, the proportion of group level variance from the total variance.

RESULTS

During the study period, 135 pediatric OSA subjects who underwent AT were enrolled. Eighty-eight children (64.6%) completed all preoperative and postoperative evaluations and were included in the analysis. The dropout rate was 17.8% in the first year, 28.9% in the second year, and 35.4% in third year, indicating the reluctance of parents to participate in long-term follow-up. The mean age at the time of screening was 8.9 ± 2.7 y. Boys were predominant in this sample ($n = 72$, 81.8% mean age 8.9 ± 2.04). The mean AHI before AT (AHI₀), was

13.53 ± 7.23 events/h and the mean BMI was 19.54 ± 4.64 kg/m². The BMI-z score revealed that our subjects were not obese. We compared the characteristics of subjects that completed the study and those that did not, and found there was no significant difference between these two groups (Tables 1 and 2).

A comparison of PSG data before and after AT showed that the baseline AHI₀ (13.53 ± 7.23 events/h; median = 6.85, range 1.2 to 49.4 events/h) had improved significantly at all post-AT yearly time points (AHI₁₂ P < 0.001, AHI₂₄ P < 0.001, AHI₃₆ P = 0.004, respectively). Rapid eye movement (REM) sleep also showed a significant increase at all post-AT yearly time points (P = 0.04, 0.016, 0.003, respectively), as did the percentage of slow wave sleep (P = 0.03, 0.02, 0.006, respectively). Median AHI also was significantly improved at all post-AT yearly time points (Tables 3 and 4).

Overall, these data indicate the positive results of surgery but do not represent the real postsurgical evolution of the AHI over time. Using a multivariate Generalized Linear Model (GLM) analysis we found a significant improvement in the AHI (mean AHI₀ = 13.54 to mean AHI₆ = 3.47 events/h) during “period 1” (pre-AT-AHI₀-to 6 mo post-AT-AHI₆-). The success rate of AT in this study at 6- mo postsurgery is therefore 46.6%. The remaining 53.4% of the children had an AHI₆ greater than one event/h following surgery.

During period 2 (6 to 36 mo post-AT) there was an AHI elevation beginning at the 6-mo time point: from mean AHI₆ = 3.47 to mean AHI₃₆ = 6.48 events/h (range: AHI₆ = 0 to 35.5 events/h to AHI₃₆ = 0 to 42.3 events/h). Though all values were significantly less than the baseline AHI (AHI₀), the mean AHI showed a significant increase from 6 to 36 mo postsurgery (Tables 3 and 4 and Figure 1). Using GLM analysis, we found persistence of a significant difference between presurgery and postsurgery PSG data, but this effect varied between different time sequences: With HLM analysis and the two-level model calculations, the coefficient in level one (fixed effects) showed again that the value of the AHI was significantly reduced during the period (AHI₀ to AHI₆), and that the significant positive gains covered not only AHI but also apnea index (AI), mean oxygen saturation, sleep latency, wake after sleep onset (WASO), and percentage of REM sleep. But in period 2, the proportion of the AHI was significantly increased: from 6 mo posttreatment to later time points (up to AHI₃₆). This AHI rebound starting 6 mo postsurgery was associated with a worsening of nocturnal sleep (WASO, sleep latency, and sleep efficiency).

Subgroup Analyses

We divided the post-AT patients into two groups. Group 1 (the successful group, n = 41) had an AHI₆ < 1 at AT+6 mo. The

Table 1—Clinical characteristics of children completing the longitudinal study versus those who dropped out during the 3 y of follow-up

	Completed group	Dropout group	P value
Number of subjects	n = 88	n = 47	
Mean age at time of screening (y old)	8.9 ± 2.7	8.6 ± 2.11	0.908
Number of males	72 (81.8%)	39 (83%)	0.375
BMI (kg/m ²) (mean ± SD) at entry	19.54 ± 4.64	20.10 ± 6.29	0.369
BMI z score at entry	-0.75 ± 1.00	-0.78 ± 0.99	0.358

BMI, body mass index; SD, standard deviation.

Table 2—Comorbidities of children completing the longitudinal study versus those who dropped out during the 3 y of follow-up

	Completed group	Dropout group	P value
Comorbidity			
PLM disorder	10 (11.4%)	1 (2.1%)	0.203
Learning disorder	14 (15.9%)	2 (4.3%)	0.068
ADHD ^a	33 (37.5%)	21 (44.7%)	0.838
Enuresis	17 (19.3%)	2 (4.3%)	0.049
Other physical comorbidity ^b			
Asthma	4 (4.5%)	1 (2.1%)	0.651
Allergic rhinitis	44 (50%)	28 (59.6%)	0.665
Eczema	4 (4.5%)	1 (2.1%)	0.713
Sinusitis	6 (7.9%)	1 (2.1%)	0.514
Dermatitis	1 (1.1%)	0 (0%)	0.796
Findings of ENT examination			
Tonsil hypertrophy (more than grade 2)	86 (97.7%)	40 (85.1%)	0.108
Adenoid hypertrophy	74 (84.1%)	41 (87.2%)	0.956
Turbinate hypertrophy	10 (11.4%)	2 (4.3%)	0.067
Nasoseptal deviation	4 (5.4%)	1 (2.1%)	0.528

^aDiagnosed according to criteria of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. ^bConfirmed and diagnosed by pediatricians. ENT, ear, nose and throat; ADHD, attention deficit hyperactivity disorder; PLM, periodic limb movement.

analysis of this subgroup, considered as initially fully treated, revealed that the recurrence rate was 35.3% after AT+12 mo, 50% after AT+24 mo, and 66.7% after AT+36 mo. Group 2 (the nonsuccessful group, n = 47) had an AHI₆ > 1 at AT+6 mo and also showed a progressive increase in the residual AHI at +36 mo. Overall, when considering worsening and recurrence, 68% of the children followed had an abnormal AHI and abnormal sleep at AT+36 mo. The mean AHI₃₆ was 6.48 ± 5.57 events/h.

Determination of risk factors for OSA recurrence after AT was based on GLM of repeated measure analysis: AHI₆ was significantly associated with BMI, body weight, AHI, and the presence of enuresis and allergic rhinitis before surgery: the risk factor of residual pediatric OSA 6 mo after AT was significantly related to BMI and body weight, severity of pediatric OSA, enuresis and rhinitis before surgery. The analyses performed in period 2 (from post-AT+6 mo to +36 mo) showed that the recurrence of pediatric OSA was significantly associated with age, persistence of enuresis, the AHI post-AT+6 mo, and a fast and abnormal increase of BMI and body weight (from

Table 3—Weight and polysomnographic data before and after adenotonsillectomy (n = 88)

	Before AT		6 mo post-AT 1		12 mo post-AT 1		24 mo post-AT		36 mo post-AT	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Bw (kg)	34.37	4.56	34.07	5.03	41.98	6.08	45.75	6.32	44.07	3.63
BMI (kg/m ²)	19.54	4.64	19.31	4.17	20.94	4.73	21.15	5.54	20.63	5.01
BMI z score	-0.75	1.00	-0.88	0.99	-0.44	0.99	-0.33	0.98	-0.37	1.00
PSG										
AHI (events/h)	13.54	7.23	3.47 ^c	2.01	6.29 ^b	5.09	4.14 ^c	4.60	6.48 ^b	5.57
Median AHI (events/h)	6.85		1.15		2.80		1.85		2.65	
AI (events/h)	4.06	3.69	1.03 ^a	0.70	1.97 ^a	0.88	1.75 ^a	1.65	1.28 ^a	1.60
WASO (%)	7.46	6.68	7.23	5.86	9.90	6.57	10.28	5.50	10.88	5.19
Mean SaO ₂	96.20	2.10	96.92 ^a	1.56	96.57	1.77	96.96	1.25	96.76	1.55

^aP < 0.05. ^bP < 0.01. ^cP < 0.001. AHI, apnea-hypopnea index; AI, apnea index; BMI, body mass index; Bw, body weight; mean SaO₂, mean oxygen saturation; PSG, polysomnography; SD, standard deviation; WASO, wake after sleep onset.

Table 4—Sleep variables before and after adenotonsillectomy (n = 88)

Sleep variables	BeforeAT		6 mo post-AT 1		12 mo post-AT 1		24 mo post-AT		36 mo post-AT	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Sleep efficiency (%)	87.26	12.72	88.73	10.52	88.48	12.59	86.28	12.82	86.14	14.29
Sleep latency (mins)	18.97	9.36	15.02 ^a	7.41	15.69 ^a	7.91	14.35 ^a	7.23	21.03	4.88
REM (%)	11.14	6.50	14.00 ^a	6.31	13.36 ^a	6.47	14.02 ^a	6.75	14.98 ^b	6.31
Stage 1 (%)	19.09	8.65	15.39	7.58	19.48	6.58	12.79	8.72	13.62	14.06
Stage 2 (%)	35.11	12.71	26.11	4.48	26.95	9.77	24.14	7.84	25.08	9.07
Stage 3+4 (%)	35.54	6.01	44.53 ^a	10.10	43.43 ^a	11.44	41.46 ^a	13.23	41.77 ^b	11.89
PLMI (times/h)	1.58	3.65	1.02	1.19	1.12	3.25	0.67	1.94	1.08	2.67

^aP < 0.05. ^bP < 0.01. REM, rapid eye movement; PLMI, periodic limb movement index.




Figure 1—Change of apnea-hypopnea index (AHI) after adenotonsillectomy using Multivariate generalized linear modeling (GLM) and the hierarchical linear model (HLM); the straight thin line indicates the significant linear increase. **Period 1** (from before AT -AHI₀ to 6 months post AT surgery -AHI₆): results showed a significant improvement in AHI (from a mean AHI₀ = 13.54 to a mean AHI₆ = 3.47 events/h). **Period 2** (from 6 mo postsurgery -AHI₆ to 36 mo postsurgery -AHI₃₆): the mean AHI significantly increased between 6 mo postsurgery to 36 mo postsurgery (mean AHI₆ = 3.47 to mean AHI₃₆ = 6.48 events/h). This increase was associated with recurrence in 68% of subjects followed for 36 mo postsurgery.

post-AT+6 mo to +12 mo, from +12 mo to +24 mo, and from +24 mo to +36 mo) (Table 5).

Six months after AT, the OSA-18 analyses showed significant improvement in the items of sleep disturbance (mean: 4.06 ± 1.52 to 2.40 ± 1.22), physical suffering (mean: 3.82 ± 2.02 to 2.79 ± 1.92), daytime problems (mean: 4.12 ± 1.98 to 3.33 ± 2.03), caregiver concerns (mean: 4.44 ± 1.78 to 3.01 ± 1.91) and total quality of life (mean: 5.12 ± 2.08 to 6.01 ± 2.95) (higher scores indicated greater severity, except the item of total quality of life, which was the reverse). However, the items of sleep disturbance, daytime problems, and caregiver concerns worsened again at +36 mo post-AT. The results of the sleep questionnaire were similar to the results of the PSG.

DISCUSSION

The limitations of this study include: (1) a somewhat small sample size, ending with 88 children and a male predominance; the dropout rate was 36% with only 88 subjects completing the 36-mo follow-up; (2) age (6 to 12 y) was taken into consideration when AT would usually be performed in Taiwan; (3) because of our institutional review board, this was not a randomized controlled trial; (4) the lack of obese children (a deliberate choice); and (5) the fact that craniofacial structure imaging data (i.e., three-dimensional computed tomography)

Table 5—The risk factors for OSA recurrence after AT

	AHI 6 months				AHI 12 months				AHI 24 months				AHI 36 months			
	Est.	S.E.	Wald Sta	P value	Est.	S.E.	Wald Sta	P value	Est.	S.E.	Wald Sta	P value	Est.	S.E.	Wald Sta	P value
Intercept	13.29	2.58	26.52	0.001	-1.93	0.6696	8.293	0.004	6.09	0.5598	118.2	0.001	4.54	0.6230	53.13	0.001
Enuresis	-4.80	0.97	24.57	0.001	0.764	0.5584	1.874	0.071	-0.70	0.1165	35.87	0.001	0.767	0.2936	6.819	0.009
Rhinitis	-1.84	0.93	3.90	0.048	-0.322	0.4877	0.436	0.509	-0.40	0.1397	12.82	0.101	0.627	0.4111	2.328	0.127
Age	-0.16	0.09	3.18	0.075	0.080	0.0702	1.302	0.084	-0.44	0.0492	80.61	0.001	-0.306	0.0829	13.63	0.001
BMI_0	-1.25	0.37	11.47	0.001												
BMI_D					0.555	0.1274	18.99	0.001	0.034	0.0071	22.57	0.001	0.070	0.0408	2.913	0.048
AHI_0	0.15	0.04	17.54	0.001												
AHI_0.5					0.253	0.0430	34.76	0.001	0.042	0.0015	743.5	0.001	0.051	0.0078	43.04	0.001
	Chi-square = 105.85, df = 5, P < 0.001				Chi-square = 85.60, df = 5, P < 0.001				Chi-square = 82.54, df = 5, P < 0.001				Chi-square = 48.51, df = 7, P < 0.001			

Generalized linear model (GLM) with normal distribution and log link function. The risk-factors for OSA recurrence after AT based on GLM of repeated measure analysis. BMI_0: means BMI before AT. BMI_D: means the change (increasing) of BMI from post-AT 6 months to 12 months; the change (increasing) of BMI from post AT 12 months to 24 months; the change (increasing) of BMI from post-AT 24 months to 36 months. Est., estimate; S.E., standard error; Wald Sta, Wald statistics.

was not performed on every child. Although a 1-y follow-up study of sleep disordered breathing with AT²⁵ has discussed the recurrence issue, our study, to the best of our knowledge, is the first prospective 3-y longitudinal study of pediatric OSA after AT. Also, the long-term follow-up of these patients was performed in the same hospital sleep center using the same recording techniques and PSG scoring criteria. Clinical evaluation was a systematic evaluation that was based on criteria established prior to the beginning of the study, and repeated psychiatric and neurocognitive testing was administered by the same team.

AT is the treatment of choice for pediatric OSA and our results showed significant improvements post-AT. However, incomplete resolution of pediatric OSA was noted in many of our children. Our results show that post-AT OSA does not spontaneously remit, and although the effect size was relatively small (66.7% of subjects), AHI did worsen over time, even if surgery was successful at 6 months posttreatment. A recent study has reported some mechanisms by which this worsening may occur.¹² Asthma was not a predictive factor for post-AT OSA in our study group, but our rate of asthma was low at the outset. This difference may be related to differing rates of asthma and triggers, differences in OSA phenotype or subtype compared to other study populations, or overall adequacy of treatment and lung function during the study period. In this study, the predictive factors of residual pediatric OSA after AT-HI₆ were BMI and body weight, severity of pediatric OSA, and enuresis and rhinitis before surgery. The recurrence and persistence of pediatric OSA was associated with enuresis, age (post-AT+24 mo to post-AT+36 mo), AT-AHI₆ (the severity of residual pediatric OSA after AT) and the change (with a fast increase) in BMI and body weight (from post-AT-AHI₆ to AHI₁₂, from post-AT-AHI₁₂ to AHI₂₄, and from post-AT-AHI₂₄ to AHI₃₆). Increases in BMI and body weight are common post-AT.¹⁷ Also, there is reluctance in our own pediatric field to perform AT with young children, and surgical treatment acceptance varies depending on culture and the pediatrician's education. At times, surgery may be delayed, and this is related to the issues that delay the treatment of OSA. Therefore, education will be an important issue to physicians in the future. Moreover, the GLM analysis in our study showed that age was a risk factor for recurrence of

OSA after AT. Age not only has an effect on oral-facial growth, with 60% of the adult face already formed by 4 y of age,²⁶ but it may favor incomplete surgical results and secondary worsening posttreatment, as age at the time of surgery was a significant variable predicting incomplete resolution of pediatric OSA. Our study supports the need to perform AT at an earlier age than it is often done in our culture and some other cultures.²⁷ Independent of age, AT overall improved OSA, but even if it appeared successful initially, as demonstrated by recordings at 6 mo postsurgery, recurrence of abnormal breathing within 1 to 3 y is important. Overall, 68% of children treated with adenotonsillectomy presented a mean AHI of 6.48 events/h. This polysomnographic finding is associated with a subjective and objective demonstration of poor sleep, and a demonstration of the worsening of symptoms associated with attention and daytime hyperactivity.

Our study outlines some risk factors, such as severe pediatric OSA, obesity, and a large increase in BMI after AT, rhinitis, enuresis, and older age for recurrence of OSA, but we do not claim to have identified all of the risk factors. Finally, an obvious conclusion of our work is that children in whom OSA is diagnosed require long-term follow-up.

ACKNOWLEDGMENTS

The authors thank professor Fan-Ming Hwang and Po-Yu Huang, PhD, for help with statistical analysis, and Shannon Sullivan, MD, for her editing of the manuscript.

DISCLOSURE STATEMENT

This was not an industry supported study. This research was supported by Chang Gung Memorial Hospital: CMRPG 470011. The authors have indicated no financial conflicts of interest.

REFERENCES

1. Schechter MS. Technical report: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics* 2002;109:e69.
2. Gozal D, Kheirandish-Gozal L. Obesity and excessive daytime sleepiness in prepubertal children with obstructive sleep apnea. *Pediatrics* 2009;123:13-8.
3. Goldstein NA, Pugazhendhi V, Rao SM, et al. Clinical assessment of pediatric obstructive sleep apnea. *Pediatrics* 2004;114:33-43.

4. Gozal D, Wang M, Pope DM Jr. Objective sleepiness measures in pediatric obstructive sleep apnea. *Pediatrics* 2001;108:693-7.
5. Nieminen P, Löppönen T, Tolonen U, Lanning P, Knip M, Löppönen H. Growth and biochemical markers of growth in children with snoring and obstructive sleep apnea. *Pediatrics* 2002;109:e55.
6. Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Spruyt K. Neurocognitive and endothelial dysfunction in children with obstructive sleep apnea. *Pediatrics* 2010;126:e1161-7.
7. Barone JG, Hanson C, DaJusta DG, Gioia K, England SJ, Schneider D. Nocturnal enuresis and overweight are associated with obstructive sleep apnea. *Pediatrics* 2009;124:e53-9.
8. Suratt PM, Barth JT, Diamond R, et al. Reduced time in bed and obstructive sleep-disordered breathing in children are associated with cognitive impairment. *Pediatrics* 2007;119:320-9.
9. Lumeng JC, Chervin RD. Epidemiology of pediatric obstructive sleep apnea. *Proc Am Thorac Soc* 2008;5:242-52.
10. Montgomery-Downs HE, O'Brien LM, Holbrook CR, Gozal D. Snoring and sleep-disordered breathing in young children: subjective and objective correlates. *Sleep* 2004;27:87-94.
11. Constantin E, Tewfik TL, Brouillette RT. Can the OSA-18 quality-of-life questionnaire detect obstructive sleep apnea in children? *Pediatrics* 2010;125:e162-8.
12. Bhattacharjee R, Kheirandish-Gozal L, Spruyt K, et al. Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children: a multicenter retrospective study. *Am J Respir Crit Care Med* 2010;182:676-83.
13. Reuveni H, Simon T, Tal A, Elhayany A, Tarasiuk A. Health care services utilization in children with obstructive sleep apnea syndrome. *Pediatrics* 2002;110:68-72.
14. Tarasiuk A, Greenberg-Dotan S, Simon-Tuval T, et al. Elevated morbidity and health care use in children with obstructive sleep apnea syndrome. *Am J Respir Crit Care Med* 2007;175:55-61.
15. Tarasiuk A, Simon T, Tal A, Reuveni H. Adenotonsillectomy in children with obstructive sleep apnea syndrome reduces health care utilization. *Pediatrics* 2004;113:351-6.
16. Mitchell RB. Adenotonsillectomy for obstructive sleep apnea in children: outcome evaluated by pre- and postoperative polysomnography. *Laryngoscope* 2007;117:1844-54.
17. Redline S, Amin R, Beebe D, et al. The childhood adenotonsillectomy trial (CHAT): rationale, design, and challenges of a randomized controlled trial evaluating a standard surgical procedure in a pediatric population. *Sleep* 2011;34:1509-17.
18. http://www.bhp.doh.gov.tw/BHPnet/Portal/Them_Show.aspx?Subject=200712250006&Class=0&No=200905050001
19. Brodsky L, Moore L, Stanievich J. A comparison of tonsillar size and oropharyngeal dimensions in children with obstructive adenotonsillar hypertrophy. *Int J Pediatr Otorhinolaryngol* 1987;13:149-56.
20. Franco RA, Rosenfeld RM, Rao M. Quality of life for children with obstructive sleep disorders. *Otolaryngol Head Neck Surg* 2000;123:9-16.
21. Wang CH, Huang YS. Clinical utility of the Obstructive Sleep Apnea Questionnaire-18 in children with obstructive sleep apnea syndrome. 2009 World Congress on Sleep Apnea (WCSA) Proceeding Korean Sleep Society, Seoul (South Korea) 2009 abstract-194.
22. Rechtschaffen A, Kales A. A manual of standardized terminology: techniques and scoring systems for sleep stages of human subjects. Los Angeles, CA: University of California, Los Angeles, Brain Information Service/Brain Research Institute, 1968.
23. American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
24. Lin CH, Guilleminault C. Current hypopnea scoring criteria underscore pediatric sleep disordered breathing. *Sleep Med* 2011;12:720-9.
25. Amin R, Anthony L, Somers V, et al. Growth velocity predicts recurrence of sleep-disordered breathing 1 year after adenotonsillectomy. *Am J Respir Crit Care Med* 2008;177:654-9.
26. Enlow DH, Poston WR. Facial Growth, 3rd ed. Philadelphia, PA: Saunders, 1990.
27. Pirelli P, Saponara M, Guilleminault C. Rapid maxillary expansion before and after adenotonsillectomy in children with obstructive sleep apnea. *Somnology* 2012;16:125-32.